Key design considerations for adaptive clinical trials: a primer for clinicians

被引:102
作者
Thorlund, Kristian [1 ,2 ]
Haggstrom, Jonas [2 ]
Park, Jay J. H. [1 ]
Mills, Edward J. [1 ,2 ]
机构
[1] McMaster Univ, Dept Hlth Res Methods Evidence & Impact HEI, Hamilton, ON, Canada
[2] Bill & Melinda Gates Fdn, Seattle, WA 98109 USA
来源
BMJ-BRITISH MEDICAL JOURNAL | 2018年 / 360卷
关键词
D O I
10.1136/bmj.k698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article reviews important considerations for researchers who are designing adaptive clinical trials. These differ from conventional clinical trials because they allow and even enforce continual modifications to key components of trial design while data are being collected. This innovative approach has the potential to reduce resource use, decrease time to trial completion, limit allocation of participants to inferior interventions, and improve the likelihood that trial results will be scientifically or clinically relevant. Adaptive designs have mostly been used in trials evaluating drugs, but their use is spreading. The US Food and Drug Administration recently issued guidance on adaptive trial designs, which highlighted general principles and different types of adaptive clinical trials but did not provide concrete guidance about important considerations in designing such trials. Decisions to adapt a trial are not arbitrary; they are based on decision rules that have been rigorously examined via statistical simulations before the first trial participant is enrolled. The authors review important characteristics of adaptive trials and common types of study modifications and provide a practical guide, illustrated with a case study, to aid investigators who are planning an adaptive clinical trial
引用
收藏
页数:5
相关论文
共 12 条
[1]   Optimizing Drug Development Programs: Type 2 Diabetes Case Study [J].
Antonijevic, Zoran ;
Kimber, Martin ;
Manner, David ;
Burman, Carl-Fredrik ;
Pinheiro, Jose ;
Bergenheim, Klas .
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2013, 47 (03) :363-374
[2]  
Atkinson AC., 2013, Randomised Response-Adaptive Designs in Clinical Trials
[3]   The reassessment of trial perspectives from interim data - a critical view [J].
Bauer, P ;
Koenig, F .
STATISTICS IN MEDICINE, 2006, 25 (01) :23-36
[4]   Innovative approaches for designing and analyzing adaptive dose-ranging trials [J].
Bornkamp, Bjoern ;
Bretz, Frank ;
Dmitrienko, Alex ;
Enas, Greg ;
Gaydos, Brenda ;
Hsu, Chyi-Hung ;
Koenig, Franz ;
Krams, Michael ;
Liu, Qing ;
Neuenschwander, Beat ;
Parke, Tom ;
Pinheiro, Jose ;
Roy, Amit ;
Sax, Rick ;
Shen, Frank .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) :965-995
[5]  
European Medicines Agency, 2017, AD PATHW 2017
[6]   In the era of systematic reviews, does the size of an individual trial still matter? [J].
Guyatt, Gordon H. ;
Mills, Edward J. ;
Elbourne, Diana .
PLOS MEDICINE, 2008, 5 (01) :3-5
[7]  
Hummel J, 2015, CLIN INVESTIG LOND, V5
[8]   Response-adaptive randomization for clinical trials with adjustment for covariate imbalance [J].
Ning, Jing ;
Huang, Xuelin .
STATISTICS IN MEDICINE, 2010, 29 (17) :1761-1768
[9]   MULTIPLE TESTING PROCEDURE FOR CLINICAL-TRIALS [J].
OBRIEN, PC ;
FLEMING, TR .
BIOMETRICS, 1979, 35 (03) :549-556
[10]   Adaptive enrichment designs for clinical trials [J].
Simon, Noah ;
Simon, Richard .
BIOSTATISTICS, 2013, 14 (04) :613-625